Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | HTR2B | P41595 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779949 | 0.86 | MAOB (0.60) | MAOBHTR2BMEN1TP53CYP1A2 | |
| SCHEMBL5779461 | 0.81 | MAOB (0.82) | MAOBHTR2BMEN1TP53CYP1A2 | |
| SCHEMBL5780884 | 0.77 | MAOB (0.51) | MAOBHTR2BMEN1TP53CYP1A2 | |
| SCHEMBL5781894 | 0.77 | MAPK11 (0.46) | MAOBHTR2BMEN1TP53CYP1A2 | |
| SCHEMBL5778627 | 0.76 | CCR2 (0.53) | MAOBHTR2BMEN1TP53CYP1A2 | |
| SCHEMBL5779412 | 0.75 | ALDH1A1 (0.48) | MEN1MAPTKMT2ANPC1RAB9A | |
| SCHEMBL27529537 | 0.74 | KMT2A (0.51) | MAOBMEN1MAPTKMT2AKDM4E | |
| SCHEMBL16131037 | 0.74 | MAOB (0.60) | MAOBCHRNA7HDAC3HDAC1 | |
| SCHEMBL8569571 | 0.74 | MAOB (0.60) | MAOBCYP3A4TSHRSMN1; SMN2CHRNA7 | |
| SCHEMBL5486894 | 0.74 | NPC1 (0.67) | MEN1MAPTKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383757-B1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK INC (US) | 2006-09-27 | — | — | EP | claimed |
| US-20040127513-A1 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. | 2004-07-01 | — | — | US | claimed |
| EP-1383757-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2004-01-28 | — | — | EP | claimed |
| US-20030092728-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-05-15 | — | — | US | claimed |
| WO-2002081463-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-10-17 | — | — | WO | claimed |
| EP-1383757-B1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK INC (US) | 2006-09-27 | — | — | EP | disclosed |
| US-6998407-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2006-02-14 | — | — | US | disclosed |
| EP-1383757-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2004-01-28 | — | — | EP | disclosed |
| US-6677365-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; RHEUMATIC DISEASES; CARDIOVASCULAR DISORDERS | TELIK, INC. | 2004-01-13 | — | — | US | disclosed |
| WO-2002081463-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092728-A1 | Antagonists of MCP-1 function and methods of use thereof | CCL11, CCR1, CCR2 | MAOB 2742/4885HTR2B 3818/4885MEN1 2213/4885 |
| US-20040127513-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | MAOB 3387/4885HTR2B 3813/4885MEN1 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.